Pharmaceutical

Image

Global Blau syndrome Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Feb 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Blau syndrome Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR - % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 7.13 Million
Diagram Market Size (Forecast Year) USD 18.16 Million
Diagram CAGR %

Global Blau syndrome Market, By Therapeutic Areas (Skin Rash, Inflammation), Route of Administration (Oral, Parenteral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030

Blau syndrome Market Analysis and Size

Several advancements in the health care industry of blau syndrome will impact in launching new product by the several manufacturers into the market, improving its demand along with availability of off-label drugs. Furthermore, every day changing technologies also puts a hindrance for physicians to perform the numerous kinds of genetic tests. Presently, numerous research studies are taking place which is projected to create a competitive advantage for manufacturers to develop advanced and innovative blau syndrome drugs which is projected to provide several other opportunities in the blau syndrome market.

 Data Bridge Market Research analyses a growth rate in the blau syndrome market in the forecast period 2023-2030. The expected CAGR of blau syndrome market is tend to be around 12.4% in the mentioned forecast period. The market is valued at USD 7.13 million in 2022, and it would grow upto USD 18.16 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Therapeutic Areas (Skin Rash, Inflammation), Route of Administration (Oral, Parenteral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Abbvie, Inc (U.S.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), Pfizer Inc. (U.S.), Amgen Inc. (U.S.), Janssen Global Services, LLC (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Fulgent Genetics (U.S.), Invitae Corporation (U.S.), Swedish Orphan Biovitrum AB (Sweden), Alkem Labs Ltd (India), Accord Healthcare (U.K.), Zydus Group (India), Amneal Pharmaceutical Inc. (U.K.), CENTOGENE N.V. (Germany)

Market Opportunities

  • Growing Treatment Options
  • Increasing Product Launches and Developments

Market Definition

Blau Syndrome typically presents in childhood with the triad of granulomatous dermatitis, arthritis, and uveitis. This syndrome is also termed as familial juvenile systemic granulomatosis. Even though a skin rash is not necessarily a ubiquitous feature of Blau syndrome, it is mostly the first sign of disease if it is available. In majority of the cases, a normal rash appears within the first year of life and presents as discrete, erythematous papules. In this condition, the most common feature which is arthritis, tends to rise between the ages of 2 to 4 years.

Blau Syndrome Market Dynamics

Drivers

  • Increasing Diagnostic Procedures

There have been increasing diagnostic procedures available which boosts the market growth. Optical coherence tomography (OCT) may be used to depict the extent of ocular disease. Skin or synovial biopsy may be used that will reveal noncaseating granulomas. Out of these two options, skin biopsy is less invasive and has showed higher accuracy. Furthermore, next generation sequencing may be used to test for causative NOD2 mutations, which will confirm the diagnosis. X-rays show dysplastic changes, such as camptodactyly, carpal dysplasia, abnormal ulna and second metacarpal bone shape, abnormal distal radial epiphysis, short ulna. Complete blood count (CBC), C-reactive protein (CRP), serum angiotensin-converting enzyme (ACE), erythrocyte sedimentation rate (ESR), antinuclear antibody (ANA), anti-neutrophilic cytoplasmic antibody (ANCA), anti-dsDNA antibody, Lyme disease serology, rheumatoid factor (RF),  RPR/VDRL, human leukocyte antigen (HLA) testing, tuberculin skin test, pathergy skin test are the types of tests that can be performed.

Opportunities

  • Growing Treatment Options

Treatment options such as corticosteroids also have utility during quiescent periods. The prolonged need for corticosteroids, along with the frequency of refractory symptoms, signifies the use of immunosuppressants such as mycophenolate mofetil, methotrexate, or azathioprine. For this reason, the wide use of monoclonal antibodies to target these cytokines has become helpful; though, variable degrees of efficacy have been witnessed in the literature. It is difficult to determine the true therapeutic benefit of these agents due to contrasting results and the relatively scarce amount of data available. Though medical management is the keystone of treatment for patients with Blau syndrome, operative intervention is also used in certain scenarios. There are many ocular diseases, wherein many inflammatory sequelae should be addressed surgically. Patients may opt to undergo joint fusion procedures because of severe, unrelenting arthritis. Thus, this boosts the market growth.

  • Increasing Product Launches and Developments

There has been rising number of product launches and developments that lead to the growth of the market. For instance, in April 2018, Swedish Orphan Biovitrum AB (publ) approval for Kineret which is a monoclonal antibody used for treatment of rare disease. This product approval aided the company to improve its products sales. Furthermore, in October 2016, Teva Pharmaceutical Industries Ltd. has completed the acquisition of Allergan’s Anda Inc which is the fourth largest distributor of generics medicines in the U.S. and majority of the Blau syndrome drugs such as methotrexate, azathioprine are widely available as generic drugs, hence this acquisition supported the company to enlarge its generic product portfolio for treatment of Blau syndrome. Thus, this boosts the market growth.

Restraints/Challenges

  • Unavailability of skilled professionals

The wide unavailability of qualified professionals who cannot treat the patients with appropriate treatments could restrict the market growth during the forecast period 2023-2030.

  • High Cost of Treatment

The increasing expenditure related with medications hinder the market growth. These inhibitors cost high and people in the developing and underdeveloped countries can lead to the under treatment of numerous patients. This hinders the market growth.

This blau syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the blau syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Blau Syndrome Market Scope

The blau syndrome market is segmented on the basis of therapeutic areas, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Therapeutic Areas

  • Skin Rash
  • Inflammation

Route of Administration

  • Oral
  • Parenteral
  • Topical
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Blau Syndrome Market Regional Analysis/Insights

The blau syndrome market is analyzed and market size insights and trends are provided by therapeutic areas, route of administration, end-users and distribution channel as referenced above.

The major countries covered in the blau syndrome market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for blau syndrome market throughout the forecasted period because of high healthcare and research & development expenditure. Also, the growing prevalence of autoimmune inflammatory diseases and increasing demand for all types of treatment boost the growth.

Asia-Pacific dominates the market because of the increased generic market players. And also the growing prevalence of rare genetic disorders boost the growth in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Blau Syndrome Market Share Analysis

The blau syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to blau syndrome market

Key players operating in the blau syndrome market include:

  • Abbvie, Inc (U.S.)
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Pfizer Inc. (U.S.)
  • Amgen Inc. (U.S.)
  • Janssen Global Services, LLC (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Hikma Pharmaceuticals PLC (U.K.)
  • Fulgent Genetics (U.S.)
  • Invitae Corporation (U.S.)
  • Swedish Orphan Biovitrum AB (Sweden)
  • Alkem Labs Ltd (India)
  • Accord Healthcare (U.K.)
  • Zydus Group (India)
  • Amneal Pharmaceutical Inc. (U.K.)
  • CENTOGENE N.V. (Germany)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The Blau syndrome Market is projected to grow at a CAGR of 12.4% during the forecast period by 2030.
The future market value of the Blau syndrome Market is expected to reach USD 18.16 million by 2030.
The major players in the Blau syndrome Market are Abbvie, Inc (U.S.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), Pfizer Inc. (U.S.), Amgen Inc. (U.S.), Janssen Global Services, LLC (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), etc.
The countries covered in the Blau syndrome Market are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Japan, China, etc.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials